Asthma is one of the most controllable common conditions, and the treatment that controls it is the inhaled steroid that calms the airway. The blue reliever most people lean on eases a flare in the moment but leaves the inflammation underneath untreated.
The picture has shifted in recent years: a low-dose steroid combined with a fast-acting opener, taken when symptoms flare, now prevents severe attacks far better than a reliever used on its own.
This page covers:
- what works
- in what order
- what is oversold
- the Chinese medicine reading by pattern
- the signs of an attack that mean call for help
Practice Ranking
Every practice we track for Asthma, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
5 practices · 2 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | Quitting Smoking Improves lung function and control; the single biggest change for a smoker. | Strong | Pro | Free to $$ | Hard | Days to Longer | |
| 2 | Breathwork & HRV Breathing retraining eases day-to-day symptoms and quality of life, though it does not change how your lungs test. | Moderate | Self-Directed | Free | Easy | Days to Weeks | |
| 3 | Zone 2 Regular aerobic training builds fitness and is safe in asthma that is reasonably controlled. | Moderate | Self-Directed | Free to $$ | Moderate | Weeks to Months | |
| 4 | Weight Loss Improves control in people with obesity. | Moderate | Self-Directed | Free to $$$ | Moderate to Hard | Weeks to Months | |
| 5 | Vitamin D No overall effect on attacks; worth correcting only a genuine deficiency. | Emerging | Supplement | $ | Easy | Weeks to Months | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
What It Is
Asthma is an inflamed, over-reactive airway. When a trigger sets it off, the airway narrows, swells, and fills with mucus, and that is the wheeze, cough, chest tightness, and breathlessness you feel. Cold air, an allergen, a cold virus, exercise, or smoke can all tip a sensitive airway into a flare. The inflammation is the disease, and the narrowing is the symptom. Different inhalers treat the two, and only the one that treats the inflammation changes the course of the condition.
Asthma comes in a few recognizable patterns:
- Allergic (eosinophilic) asthma is the most common. It is driven by an allergic type of inflammation, often runs alongside hay fever and eczema, frequently starts in childhood, and responds best to inhaled steroids.
- Non-allergic asthma more often begins in adulthood, is sometimes linked to weight or aspirin sensitivity, and can be less steroid-responsive.
- Exercise-induced bronchoconstriction is wheeze that comes on during or shortly after exertion, especially in cold, dry air. It is a reason to control the asthma, not to stop exercising.
- Severe asthma keeps flaring despite high-dose inhaled steroids taken correctly, often with a high eosinophil count. This is the group modern biologic drugs were built for.
Asthma, hay fever, and eczema tend to occur together as one allergic tendency, so an uncontrolled nose can worsen the chest below it.
What controls it
Asthma treatment has a clear order, and one rule matters most.
The controller inhaler is the core treatment. Feeling well is what it is doing, so it is taken every day and not stopped when symptoms quiet down.
A daily inhaled corticosteroid, the controller, calms the airway inflammation that drives asthma, and it is the treatment that changes the disease. In the START trial of 7,241 people with recent, mild asthma, a low daily dose nearly halved the risk of a severe attack over three years (hazard ratio 0.56). The blue reliever does the opposite job: it opens the airway for a few hours and leaves the inflammation untouched, so it is never a substitute for the controller.
The larger shift of recent years is in what you reach for when symptoms flare. A low-dose steroid combined with fast-acting formoterol, taken only as needed, prevents severe attacks far better than a plain blue reliever used alone. It cut severe attacks to about a third of the reliever-alone rate in the SYGMA 1 trial, and about in half in the real-world Novel START trial, while using far less steroid than a daily controller. Even the as-needed inhaler can carry an anti-inflammatory. This is a change to make with your prescriber.
How fast you go through the reliever is itself a reading of control. In the SABINA cohort of 365,324 people, those going through more than two reliever canisters a year had steadily more attacks and a higher risk of dying, the risk climbing with each extra canister, up to 77% more attacks in people collecting 11 or more a year. Heavy use partly marks worse asthma to begin with, so it does not prove the reliever itself causes the harm, but a canister running down fast is a reliable prompt to have the treatment reviewed.
Then come the levers that support the core treatment and never replace it:
- Inhaler technique and not smoking. Much of the disappointment with inhalers comes down to how they are used, so a few minutes having your technique checked makes a large difference to how well the treatment works. Smoking counts just as much: in a crossover trial, non-smokers with asthma improved clearly on a course of steroid tablets, with FEV1 up 237 mL, while active smokers got no benefit on any measure, and ex-smokers responded partway. Smoking blunts the very treatment that controls asthma, and stopping restores some of the response.
- Losing weight, if you carry extra. In a randomized trial, a loss of 5 to 10% of body weight improved asthma control in 58% of overweight and obese adults and quality of life in 83%. It works on the weight-linked part of asthma alongside inhaler treatment.
- Staying active. Across 21 trials, regular training raised fitness by 4.92 mL/kg/min of oxygen uptake, improved quality of life, was well tolerated, and did not worsen asthma. If exercise reliably brings on symptoms, that points to asthma that needs better control first, not a reason to stop moving.
- Breathing retraining. In a Cochrane review of 22 trials and the 655-adult BREATHE trial, it improved asthma quality of life by 0.42 on the AQLQ, with little change in lung function or airway inflammation. It eases symptoms and coping; it does not treat the disease underneath, so it belongs alongside a controller inhaler and cannot stand in for one.
Two treatments are aimed at specific groups:
- Allergen immunotherapy, where a confirmed allergy clearly drives the asthma, lowered symptoms and the medication people needed across 88 trials. Injection immunotherapy carries a small but meaningful risk of a serious allergic reaction, about one in nine people having a systemic reaction, so it is given where staff can treat one.
- A biologic, for severe asthma that keeps flaring despite correctly used high-dose inhaled steroids, roughly halves attacks in the subgroup whose inflammation is eosinophilic. In the MENSA trial, mepolizumab cut exacerbations by about half, 47 to 53%, in people identified by a high blood eosinophil count. Biologics are specialist treatments layered on top of inhaled steroids, confirmed with blood tests first.
To recover from a bad attack, a short course of steroid tablets cut the chance of relapsing in the first week (relative risk 0.38) and reduced return hospital visits, with no clear rise in side effects. It is a rescue course started early, not a daily medicine, which is one more reason a severe attack needs prompt medical care.
Each finding below is graded at the strength of its own evidence.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Respiratory
A daily inhaled steroid nearly halved severe attacks over three years
A low daily dose of an inhaled steroid nearly halved the chance of a severe asthma attack over three years, compared with a dummy inhaler, in people with early, mild asthma. It works by calming the airway over time, so it is taken every day whether or not you feel symptoms.
In the START trial, 7,241 people aged 5 to 66 with mild persistent asthma of recent onset were randomized to once-daily low-dose inhaled budesonide or placebo for 3 years on top of usual medication. The time to a first severe asthma-related event was longer on budesonide: 117 of 3,597 on budesonide versus 198 of 3,568 on placebo had at least one severe exacerbation, a hazard ratio of 0.56 (95% CI 0.45 to 0.71). The steroid group also needed fewer courses of oral steroids and had more symptom-free days. Measured in: 7,241 people aged 5 to 66 with mild persistent asthma of less than two years' duration, not previously on regular steroids, in a randomized double-blind trial across 32 countries. This was a mild, recent-onset population, so the size of the benefit will differ in longer-standing or more severe asthma, and the low-dose inhaled steroid slightly reduced three-year growth in the youngest children (by about 0.5 inches (1.3 cm)). It calms inflammation over time rather than opening the airway on the spot, so it is taken every day, not for symptoms.
Who this may not transfer to:Both sexes were enrolled across children and adults; the trial does not report the exacerbation effect separately by sex.
Treat the controller inhaler as the core of asthma treatment and take it daily, not only when symptoms flare. The benefit builds with regular use and fades if it is stopped.
The study · 1
Pauwels et al., early intervention with budesonide in mild persistent asthma (the START trial), a randomised double-blind trial · Lancet 2003;361(9363):1071-1076
An as-needed steroid-formoterol reliever cut severe attacks to about a third of a blue reliever's rate
Taking a combined steroid-and-opener inhaler only when symptoms flared cut severe attacks to about a third of the rate seen with a plain blue reliever used the same way, and used far less steroid than a daily controller. This is the modern move away from reaching for a blue inhaler alone.
In the SYGMA 1 trial, 3,849 people aged 12 and over with mild asthma were randomized to an as-needed inhaled steroid-plus-formoterol combination, an as-needed short-acting reliever (terbutaline) alone, or maintenance budesonide plus reliever. The annual rate of severe exacerbations was 0.07 with the as-needed steroid-formoterol versus 0.20 with the reliever alone, a rate ratio of 0.36 (95% CI 0.27 to 0.49), while delivering only about 17% of the inhaled steroid dose of daily maintenance therapy. Measured in: 3,849 people aged 12 and over with mild asthma in a 52-week randomized double-blind trial. This is mild asthma, where whether a daily controller is even needed is a fair question; the as-needed steroid-formoterol matched the exacerbation protection of daily maintenance steroid while using far less steroid, but daily maintenance gave slightly better day-to-day symptom control. It is not a license to skip a prescribed daily controller in moderate or severe asthma.
Who this may not transfer to:Both sexes were enrolled; the trial does not report the exacerbation rate separately by sex.
If you have mild asthma and rely on a reliever, ask whether a combined steroid-formoterol reliever is right for you. Even your as-needed inhaler can carry an anti-inflammatory, not just an opener.
The study · 1
O'Byrne et al., inhaled combined budesonide-formoterol as needed in mild asthma (SYGMA 1) · N Engl J Med 2018;378(20):1865-1876
An as-needed steroid reliever cut everyday attacks about in half in real-world use
In a study designed to look like ordinary life, adults using a combined steroid-and-opener inhaler only when needed had about half the attacks of those using a plain blue reliever the same way. It backs up the tighter lab trials with real-world behavior.
The open-label Novel START trial randomized 668 adults with mild asthma to as-needed albuterol (a blue reliever), daily maintenance budesonide plus albuterol, or as-needed budesonide-formoterol, with inhaler use electronically monitored to mirror real practice. The annual exacerbation rate was 0.195 with budesonide-formoterol versus 0.400 with albuterol alone (relative rate 0.49, 95% CI 0.33 to 0.72), and severe exacerbations numbered 9 versus 23 (relative risk 0.40). Measured in: 668 adults with mild asthma in a 52-week open-label randomized controlled trial reflecting everyday practice. Being open-label, people knew which inhaler they had, which can shape behavior, though the electronic monitoring limited guessing about adherence. It confirms in a real-world design what the blinded trials showed, in adults with mild asthma rather than more severe disease.
Who this may not transfer to:Both sexes were enrolled; the trial does not report the exacerbation rate separately by sex.
The everyday takeaway matches the blinded trials: an as-needed inhaler that carries a steroid protects better than a blue reliever alone. Discuss the switch with your prescriber rather than changing inhalers on your own.
The study · 1
Beasley et al., controlled trial of budesonide-formoterol as needed for mild asthma (Novel START) · N Engl J Med 2019;380(21):2020-2030
In severe eosinophilic asthma, a biologic cut attacks by about half (47 to 53%)
For people whose severe asthma keeps flaring despite high-dose inhaler treatment, and who have a high level of a specific inflammatory cell, an injected biologic roughly halved their attacks. It is for that specific severe group, added on top of inhaled steroids.
In the MENSA trial, 576 people with severe asthma, recurrent exacerbations and eosinophilic inflammation despite high-dose inhaled steroids were randomized to mepolizumab (an anti-interleukin-5 antibody) or placebo every four weeks for 32 weeks. Exacerbations fell by 47% with intravenous and 53% with subcutaneous mepolizumab versus placebo, with a further drop in exacerbations needing emergency or hospital care, and improved quality-of-life and control scores. Measured in: 576 people with severe eosinophilic asthma and recurrent exacerbations despite high-dose inhaled steroids, in a randomized double-blind trial. This is for a specific severe, eosinophilic subgroup identified by blood tests, not for asthma in general, and the lung-function gain was modest (about 100 mL of FEV1). Biologics are specialist, injected treatments layered on top of inhaled steroids, not a replacement for them.
Who this may not transfer to:Both sexes were enrolled; the trial does not report the exacerbation reduction separately by sex.
If your asthma stays severe despite correctly used high-dose inhalers, ask a specialist about testing your eosinophil count and whether a biologic fits. It is added to, not swapped for, your inhaled steroids.
The study · 1
Ortega et al., mepolizumab treatment in patients with severe eosinophilic asthma (MENSA) · N Engl J Med 2014;371(13):1198-1207
Breathing retraining improved quality of life by 0.42 on the AQLQ but not lung function
Breathing retraining made people's asthma feel better and improved their quality of life, but it did not change lung function or the inflammation in the airways. It helps how you cope with asthma; it does not treat the disease, so it goes alongside a controller inhaler.
A Cochrane review of 22 trials (2,880 participants) found breathing exercises improved asthma quality of life on the AQLQ at three months (mean difference 0.42, 95% CI 0.17 to 0.68; moderate-certainty evidence) and eased hyperventilation symptoms, with inconclusive effects on lung function. The large BREATHE randomized trial (655 adults) confirmed a quality-of-life gain over usual care (adjusted mean difference 0.28) with no significant change in FEV1 or exhaled nitric oxide. Measured in: Adults with mild to moderate asthma; 2,880 across 22 trials in the Cochrane review, and 655 with incompletely controlled asthma in the BREATHE trial. The benefit is on how the asthma feels and on breathing-pattern symptoms, not on lung function or airway inflammation, which did not change. That is exactly why it belongs alongside a controller inhaler and cannot replace one: it does not treat the underlying disease.
Who this may not transfer to:Both sexes were enrolled across the pooled trials and the BREATHE trial; effects are not reported separately by sex.
Breathing retraining is worth trying for symptoms and quality of life, ideally taught by a physiotherapist or from a validated program, while keeping your controller inhaler going. Do not use it as a reason to reduce medication.
The studies · 2
Santino et al., breathing exercises for adults with asthma · Cochrane Database Syst Rev 2020;3(3):CD001277
Bruton et al., physiotherapy breathing retraining for asthma (BREATHE), a randomised controlled trial · Lancet Respir Med 2018;6(1):19-28
Losing 5 to 10% of body weight improved asthma control in 58% and quality of life in 83%
In overweight and obese adults with asthma, losing 5 to 10% of body weight improved asthma control in most people and quality of life in the large majority. It works on the weight-linked part of asthma and is a lever worth using if you are carrying extra weight.
A randomized trial in 46 overweight and obese adults with asthma compared 10 weeks of dietary restriction, exercise, or both. Weight loss averaged 8.5% with diet and 8.3% with the combined program. A loss of 5 to 10% of body weight produced a clinically important improvement in asthma control in 58% of participants and in quality of life in 83%, and the diet and combined arms improved asthma control scores significantly. Measured in: 46 overweight and obese adults with asthma (54% female, mean BMI 33.7) in a randomized trial of diet, exercise or both. The trial was small and short, and the benefit applies to overweight and obese asthmatics rather than to people of healthy weight. Weight loss works on the weight-linked component of asthma; it complements inhaler treatment rather than replacing it.
Who this may not transfer to:Both sexes were enrolled (54% female); some inflammatory findings differed by sex, but the asthma-control benefit of weight loss was seen across the group.
If you are overweight and have asthma, a 5 to 10% weight loss is a worthwhile target that can meaningfully improve control, alongside your usual inhalers rather than instead of them.
The study · 1
Scott et al., dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma, a randomized trial · Clin Exp Allergy 2013;43(1):36-49
Allergen immunotherapy eased allergic-asthma symptoms and cut medication, with about a one-in-nine reaction risk
For asthma driven by a confirmed allergy, immunotherapy given over years lowered symptoms and the medication people needed. It is aimed at the allergy itself, but injections carry a small risk of a serious allergic reaction, so they are done where that can be treated.
A Cochrane review of 88 trials of allergen-specific injection immunotherapy for asthma found a significant reduction in asthma symptoms (standardized mean difference -0.59, 95% CI -0.83 to -0.35) and in medication use, and improved bronchial hyper-reactivity. Roughly three people needed treatment to prevent one deterioration in symptoms. Around one in nine developed a systemic allergic reaction of some severity, so it carries a risk of anaphylaxis. Measured in: Adults and children with allergic asthma across 88 randomized controlled trials of allergen-specific immunotherapy. This treats asthma driven by a confirmed allergen and is a multi-year commitment, and injection immunotherapy carries a small risk of a severe allergic reaction, so it is given where staff can treat one. It reduced symptoms and medication without a consistent effect on lung function.
Who this may not transfer to:Both sexes and both children and adults were included across the pooled trials; effects are not reported separately by sex.
Immunotherapy is worth discussing when a specific allergy clearly drives your asthma and symptoms persist despite good inhaler treatment. It needs allergy testing first and a clinic set up to handle a reaction.
The study · 1
Abramson et al., injection allergen immunotherapy for asthma · Cochrane Database Syst Rev 2010;(8):CD001186
Smokers with asthma got no benefit from steroid tablets that lifted non-smokers' FEV1 237 mL
People with asthma who smoked got no benefit from a two-week course of steroid tablets, while non-smokers improved clearly. Ex-smokers responded partway, which suggests quitting brings some of the response back. Smoking undercuts the very treatment that controls asthma.
A randomized placebo-controlled crossover study gave two weeks of oral prednisolone to smokers, ex-smokers and never-smokers with asthma. Never-smokers improved significantly on prednisolone (FEV1 rose by a mean 237 mL, morning peak flow by 36.8 L/min, and asthma control scores improved), while active smokers showed no significant change on any measure. Ex-smokers fell in between, improving on peak flow but not FEV1 or control. Measured in: Adults with chronic stable asthma, grouped as smokers, ex-smokers and never-smokers, in a randomized placebo-controlled crossover trial. This tested short-term oral steroids, and the same steroid resistance is thought to extend to inhaled steroids in smokers, though this trial did not measure that. Smoking undermines the treatment that controls asthma, and stopping restores some of the response, as the ex-smoker results suggest.
Who this may not transfer to:Both sexes were enrolled; the trial does not report the steroid response separately by sex.
If you have asthma and smoke, stopping is one of the highest-value things you can do, since it restores how well your steroid inhaler and tablets work. Support to quit is worth asking for specifically on these grounds.
The study · 1
Chaudhuri et al., cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma · Am J Respir Crit Care Med 2003;168(11):1308-1311
Vitamin D did not reduce asthma attacks overall, with any benefit limited to severe deficiency
An early pooling of trials suggested vitamin D cut asthma attacks, especially in people who were very deficient. But adding newer trials in a 2023 review erased the average benefit. So it is a mixed picture, with any real effect likely limited to people who start out severely low in vitamin D.
An earlier individual-participant meta-analysis (955 people, seven trials) found vitamin D reduced the rate of exacerbations needing systemic steroids (adjusted incidence rate ratio 0.74, 95% CI 0.56 to 0.97), with the clearest benefit in people with very low baseline vitamin D. An updated 2023 Cochrane review of 20 trials (2,225 participants), including newer studies, found no reduction overall in the proportion having an exacerbation (odds ratio 1.04, 95% CI 0.81 to 1.34). Profound vitamin D deficiency was rare in these trials. Measured in: Children and adults with mostly mild to moderate asthma across up to 20 randomized placebo-controlled trials. The picture is mixed: the early signal appeared, but adding later trials washed out the average benefit, and any effect looks confined to people who start out severely deficient rather than the general asthma population. Correcting a true deficiency is reasonable on its own terms; vitamin D is not a reliable way to prevent attacks in people who are already replete.
Who this may not transfer to:Both sexes and both children and adults were included; the pooled analyzes do not show a consistent difference by sex.
If a blood test shows you are clearly deficient, correcting that is worthwhile in itself. Do not rely on vitamin D as an asthma treatment or as a reason to ease off your inhalers.
The studies · 2
Jolliffe et al., vitamin D supplementation to prevent asthma exacerbations, a systematic review and meta-analysis of individual participant data · Lancet Respir Med 2017;5(11):881-890
Williamson et al., vitamin D for the management of asthma · Cochrane Database Syst Rev 2023;2(2):CD011511
Acupuncture did not improve lung function in asthma versus sham
Across small trials, acupuncture did not improve lung function in asthma compared with a fake-needle procedure. The studies were weak, so it is not a firm verdict, but there is no good evidence it improves the breathing measures, and it does not replace a controller inhaler.
A Cochrane review of 11 trials (324 participants) of acupuncture for asthma found no statistically significant or clinically relevant effect compared with sham acupuncture. Pooled lung-function data from two trials gave a standardized mean difference of 0.12 (95% CI -0.31 to 0.55) for post-treatment FEV1. Trial quality was low and the types of acupuncture and outcomes varied widely. Measured in: 324 people with asthma across 11 randomized or possibly randomized trials of acupuncture. The trials were small and poorly reported, so this is a weak evidence base rather than a firm verdict, and some studies used points on the sham arm that traditional Chinese medicine also uses for asthma, blurring the comparison. On what exists, acupuncture has not been shown to improve lung function, so it does not substitute for controller treatment.
Who this may not transfer to:Both sexes were included across the small trials; effects are not reported separately by sex.
If you find acupuncture helpful for wellbeing, there is no reason to avoid it, but do not use it in place of your asthma inhalers or expect it to improve your lung function.
The study · 1
McCarney et al., acupuncture for chronic asthma · Cochrane Database Syst Rev 2004;(1):CD000008
Cardiorespiratory Fitness
Regular exercise raised fitness by 4.92 mL/kg/min without worsening asthma
Regular exercise made people with asthma noticeably fitter and did not make their asthma worse. It improves fitness and how you feel rather than the asthma itself, so the message is to stay active once your asthma is controlled, not to avoid exercise.
A Cochrane review of 21 trials (772 people aged 8 and over) found physical training raised maximum oxygen uptake by 4.92 mL/kg/min (95% CI 3.98 to 5.87), a clinically meaningful fitness gain, with signals of better quality of life. Training was well tolerated, no study reported worsening of asthma, and lung-function measures such as FEV1 did not change. Measured in: 772 people aged 8 and over with asthma across 21 randomized trials of physical training. Exercise improves fitness and wellbeing rather than the asthma itself, and it should be undertaken on a controlled baseline, since exercise can trigger symptoms in poorly managed asthma. The trials studied people whose asthma was stable enough to train.
Who this may not transfer to:Both sexes were enrolled across the pooled trials; effects are not reported separately by sex.
If your asthma is controlled, build regular activity in, and use a reliever or pre-exercise dose beforehand if exercise brings on symptoms. If exercise reliably triggers bad symptoms, that is a sign the underlying asthma needs better control first.
The study · 1
Carson et al., physical training for asthma · Cochrane Database Syst Rev 2013;(9):CD001116
Where the evidence does not hold up
Two things asked about often do less than people hope.
Vitamin D looked promising in an early pooling of trials, especially for people who were very deficient, but adding newer studies in a 2023 Cochrane review washed out the average benefit. The picture is mixed, and it is not a reliable way to prevent attacks in someone already replete. Correcting a confirmed deficiency is reasonable on its own terms.
Acupuncture, across 11 small trials, did not improve lung function compared with a sham needle procedure. The trials were weak, so this is a limited evidence base rather than a firm verdict, and on what exists acupuncture has not been shown to move the breathing measures. If you find it helpful for wellbeing there is no reason to avoid it, and it does not replace a controller inhaler.
Getting Asthma Under Control
None of this replaces the plan your prescriber has you on; it is how to get the most from it. Take the controller every day, treat a fast-emptying reliever as a signal to get reviewed, and reduce the things that set the airways off.
The controller calms the inflammation over days and weeks, so it only works if it is taken daily, including on the days you feel fine. Feeling well is the controller doing its job, not a reason to skip it.
Much of the disappointment with inhalers comes down to how they are used. A few minutes with a pharmacist or nurse checking your technique, and adding a spacer where it helps, gets far more of the dose to the airway.
Needing the blue reliever more than about twice a week, or a canister running down fast, means the asthma is not controlled. That is a prompt to have the treatment reviewed, not a reason to keep topping up the reliever.
A written plan sets out your daily treatment, what to do as symptoms build, and when to seek urgent help. On paper, it gives you clear steps to follow on a bad day instead of guesswork.
Reduce the exposures that set your airways off, and keep any hay fever treated, since the nose and the chest are one airway. Stopping smoking is one of the highest-value moves there is, because smoking blunts how well the steroids work.
Exercise builds fitness and does not worsen well-controlled asthma, and a 5 to 10% weight loss meaningfully improves control if you are overweight. Both work alongside your inhalers, not instead of them.
Go Deeper
- Breathing retraining: the technique that improves how asthma feels and quality of life, used alongside the controller inhaler.
- Walking and exercise: why staying active builds fitness without worsening controlled asthma, and how to start.
- Whole foods: the eating shift behind the weight loss that improves control in overweight adults.
- Pranayama: the yogic breathing exercises studied in asthma, what they improve, and what they do not change.
The Chinese Medicine View
The Chinese Medicine View
Chinese medicine reads asthma as Xiao Zheng (哮症), wheezing with an audible sound, and Chuan Zheng (喘症), labored panting breath, the two often named together as Xiao Chuan. The central idea is a hidden reservoir of Phlegm in the Lung that a trigger, cold air, an allergen, exertion or emotion, stirs into an attack. The classical approach separates the two states: treat the branch during an attack by opening the Lung and moving Phlegm, and treat the root between attacks by strengthening the organs that let Phlegm gather. A practitioner is the right way to work with this, and would read an acute attack as a Cold or a Hot pattern and trace recurrent asthma to a deficiency of the Lung, Spleen or Kidney. Read the patterns below as an interpretive lens, not a map of your lung-function test, and as an adjunct: an asthma attack is treated as an emergency, and a controller inhaler is not something to set aside for herbs.
An acute attack brought on by cold: wheezing with a tight chest, thin white or foamy sputum, no thirst, worse in cold air or winter. The Phlegm is read as cold and watery. The classical direction is to warm the Lung, scatter Cold and transform Phlegm, the picture She Gan Ma Huang Tang is built for.
An acute attack running hot: loud wheezing, a full chest, thick yellow sputum that is hard to bring up, thirst, a flushed face, worse in heat. The direction is to clear Heat, transform Phlegm and calm the wheezing, the picture of a formula such as Ding Chuan Tang.
The chronic root in many people: breathlessness on exertion, a weak voice, sweating easily, catching every cold, poor appetite, loose stools and tiredness. The Spleen is seen as producing the Phlegm that the Lung then stores. The direction is to strengthen the Lung and Spleen and stop Phlegm forming.
Long-standing asthma where the breath cannot settle: shortness of breath worse on exertion and on breathing in, cold limbs, weak lower back and knees, worse in winter. The Kidney is seen as failing to grasp the Qi and hold the breath down. The direction is to warm and tonify the Kidney so it can anchor the breathing.
Cautions
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
A short steroid-tablet course after an attack cut relapse in the first week (relative risk 0.38)
A Cochrane review of six trials (374 people) found that a short course of corticosteroids given after treatment for an acute asthma attack cut the chance of relapsing and needing more care in the first week (relative risk 0.38, 95% CI 0.20 to 0.74), an effect maintained over 21 days, with fewer subsequent hospitalizations (relative risk 0.35) and less need for the reliever, and no clear rise in side effects. As few as ten people needed treating to prevent one relapse. This is a short rescue course to recover from a flare, not a long-term treatment, since prolonged oral steroids carry their own risks. Starting it early in a bad attack is what the evidence supports, which is one reason a severe attack needs prompt medical assessment.Rowe et al., corticosteroids for preventing relapse following acute exacerbations of asthma
Heavy blue-reliever use tracked with up to 77% more attacks and a higher death risk
The SABINA nationwide cohort linked Swedish registries for 365,324 asthma patients aged 12 to 45 followed a mean of about seven years. Overuse of the short-acting reliever, defined as more than two canisters a year, was common (30% of patients) and rose in step with risk. Compared with two or fewer canisters a year, collecting 3 to 5 carried a 26% higher exacerbation risk, 6 to 10 a 44% higher, and 11 or more a 77% higher; for mortality the hazard ratios were 1.26, 1.67 and 2.35 respectively (2,564 deaths observed). This is an observational association, so it does not establish that the reliever itself causes the harm; the amount a person gets through is partly a marker of how bad and how poorly controlled their asthma already is. Either way, a canister running down fast is a reliable signal that the asthma needs reviewing rather than more reliever.Nwaru et al., overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality, the global SABINA programme
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
When to See Someone
Most asthma is very controllable, and one rule matters most: nothing on this page is a reason to stop or cut back a controller inhaler. Feeling well is what the controller is doing, and stopping it lets the inflammation come back quietly. These are the signs to act on, and the first is an emergency:
- A severe attack: too breathless to speak a full sentence, walk, or lie flat; the reliever not working or wearing off within an hour; lips or fingertips turning blue or gray; exhaustion or drowsiness; or a chest that has gone quiet with no wheeze left. Call emergency services and keep taking the reliever while you wait(seek urgent care)
- Needing the reliever inhaler more than about twice a week, or waking at night with asthma, which means the asthma is not controlled and the treatment needs reviewing with your doctor
- A peak flow reading that is dropping, or falling well below your personal best, especially alongside more symptoms, which can warn of a flare building before you feel it
- Symptoms getting steadily worse over several days despite using your inhalers as usual, which is a reason to be seen rather than to wait it out
- A new or worsening wheeze, cough or breathlessness in someone with hay fever or eczema, since asthma often occurs alongside them, and a chest that has begun to react should be assessed
- A first-ever episode of wheeze and breathlessness in an adult, or breathlessness with chest pain, a fast heartbeat, or swelling in the legs, which can be something other than asthma and needs a proper diagnosis(seek urgent care)
None of this is meant to alarm you. Asthma is very manageable for most people, and these signs simply help you tell an ordinary symptom day from an attack, and keep the controller going in between.
Common Questions
Do I really need the controller inhaler if I feel fine?
Yes, and feeling fine is the reason it is working. The controller calms the airway inflammation slowly, so its protection builds with daily use and fades if it is stopped. In the START trial a low daily dose nearly halved the risk of a severe attack over three years. Stopping it because the symptoms have quieted down lets the inflammation return without warning, which is how a settled asthma turns into a sudden flare.
What is the difference between the blue and the brown inhaler?
They do different jobs. The blue reliever opens the airway for a few hours and eases a flare in the moment, but leaves the inflammation untouched. The controller, often a brown or colored inhaler, calms that inflammation over time and is the treatment that changes the disease. The modern shift is that even your as-needed inhaler can carry a steroid: a low-dose steroid combined with formoterol, taken when symptoms flare, prevents severe attacks far better than a blue reliever used on its own.
Is it safe to exercise with asthma?
Once the asthma is controlled, exercise is good for it. Across 21 trials, regular training raised fitness and quality of life, was well tolerated, and did not worsen asthma. If exercise reliably brings on wheeze, warm up, use a reliever or pre-exercise dose as your clinician advises, and treat it as a sign the underlying asthma needs better control rather than a reason to give up activity.
Do natural remedies work for asthma?
Some help with how asthma feels, and none replace a controller inhaler. Breathing retraining improved quality of life without changing lung function, so it eases coping alongside treatment. Vitamin D showed an early signal that later trials washed out, leaving a mixed picture. Acupuncture has not been shown to improve lung function against a sham procedure. Any of these can sit alongside a controller inhaler; the danger is only in using them in place of it.
When is an asthma attack an emergency?
When the reliever is not working, you are too breathless to speak a full sentence, walk or lie flat, your lips or fingertips turn blue or gray, or you become exhausted or drowsy. A chest that has gone quiet with no wheeze left is also a danger sign. Any of these means call emergency services and keep taking the reliever while you wait for help.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 15 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.